Literature DB >> 10717174

Prognostic Factors in Hodgkin's Disease.

.   

Abstract

Prognostic factors in Hodgkin's disease (HD) are reviewed. The Ann Arbor staging classification remains the basis for evaluation of patients with HD. However, subgroups of patients with differing prognoses exist within the individual stages. In pathological stages I and II, the number of involved regions and the tumor mass in each region are important, and an estimate of the total tumor burden has proved significant. B symptoms, histological subtype, age, and gender are also generally significant but less important. Prognostic factors for laparotomy findings in clinical stages I and II are: number of involved regions, disease confined to upper cervical nodes, B symptoms, gender, histology, age, and mediastinal disease (variable influence). In clinical stages I and II, the same prognostic factors apply as for pathological stages I and II and for laparotomy findings, and also some indirect indicators of extent of disease such as erythrocyte sedimentation rate, anemia, and serum albumin. In advanced disease the number of involved nodal and extranodal regions, the total tumor burden, B symptoms, age, gender, histology, and a number of hematologic and biochemical indicators are significant. Research into serum values of certain HD-associated antigens and cytokines may in the future provide valuable tumor markers in HD.

Entities:  

Year:  1996        PMID: 10717174     DOI: 10.1053/SRAO00600146

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  3 in total

1.  The expression of Ki-67 and Bcl-2 in Hodgkin's lymphoma: correlation with the International Prognostic Score and bulky disease: a study by the Serbian Lymphoma Study Group (SLG).

Authors:  Ljubomir R Jakovic; Biljana S Mihaljevic; Maja D Perunicic Jovanovic; Andrija D Bogdanovic; Vesna M Cemerikic Martinovic; Tamara K Kravic; Vladimir Z Bumbasirevic
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

2.  Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.

Authors:  Anne-Marie Charpentier; Debra L Friedman; Suzanne Wolden; Cindy Schwartz; Bethany Gill; Jenna Sykes; Alisha Albert-Green; Kara M Kelly; Louis S Constine; David C Hodgson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-01       Impact factor: 7.038

3.  Evaluation correlates C-reactive protein with advanced stage Hodgkin's lymphoma and response to treatment in a tertiary university hospital in Brazil.

Authors:  Talita Máira Bueno da Silveira da Rocha; Ana Luiza Pereira Miranda Silva; Sérgio Costa Fortier; Carlos Sérgio Chiattone
Journal:  Rev Bras Hematol Hemoter       Date:  2015-06-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.